Medicago says it has broken ground on a $245 million biotech complex in Quebec City.
The factory will come into operation in the winter of 2021. The first doses of vaccines from the new facilities are expected for the 2023 influenza season. The plant will be able to meet the Canadian demand, while also committing much of its capacity to global markets and exporting a Canadian innovation around the world.
The Quebec City production factory will complement the one of Durham, North Carolina. It will allow Medicago to position itself as a quick responder in case of pandemic situation with influenza virus or other emerging infectious diseases in North America, the company says in a statement.
The manufacturing complex in the Estimauville Innovation Area includes the company’s headquarters, research and development as well as production facilities.
In addition to the recently-announced project, Medicago says also plans to invest close to $800 million in capital and operating expenses in its Quebec City operations over the next 10 years.
